文献速递甲状腺疾病

基线TSH水平升高、TgAb阳性及既往使用雷莫西尤单抗或酪氨酸激酶抑制剂是PD-L1阻断治疗中甲状腺功能障碍的危险因素

Elevated TSH Level, TgAb, and Prior Use of Ramucirumab or TKIs as Risk Factors for Thyroid Dysfunction in PD-L1 Blockade.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

该真实世界研究纳入148例接受PD-L1抗体治疗的患者,每6周监测甲状腺功能至24周。15例(10.1%)发生甲状腺功能障碍。多因素分析显示基线TSH升高、基线TgAb阳性及既往使用雷莫西尤单抗或多靶点酪氨酸激酶抑制剂与甲状腺功能障碍发生显著相关。

要点

  • 148例PD-L1抗体治疗患者中15例(10.1%)发生甲状腺功能障碍。
  • 基线TSH升高、TgAb阳性、既往RAM或多靶点TKI治疗者甲状腺功能障碍发生率显著更高。
  • 多因素分析OR分别为7.098、11.927、8.476,提示可用于风险预测。

核心结论

  • 真实世界研究结果提示,PD-L1抗体诱导的甲状腺功能障碍风险可通过基线TSH水平、基线TgAb阳性及既往使用雷莫西尤单抗或多靶点酪氨酸激酶抑制剂进行预测。

研究设计与样本

  • 真实世界研究,纳入148例接受PD-L1抗体治疗的患者,基线评估抗甲状腺抗体,治疗开始后每6周监测甲状腺功能至24周,随后观察至随访停止。

主要发现

  • 148例中15例(10.1%)在PD-L1抗体治疗后发生甲状腺功能障碍,其中破坏性甲状腺炎8例,无前期甲状腺毒症的甲状腺功能减退7例。
  • 基线TSH水平升高者比例在甲状腺功能障碍组为3/15(20.0%),无甲状腺功能障碍组为4/133(3.0%),P < .05。
  • 基线TgAb阳性者比例在甲状腺功能障碍组为4/15(26.7%),无甲状腺功能障碍组为5/133(3.8%),P < .05。
  • 既往使用雷莫西尤单抗或多靶点酪氨酸激酶抑制剂者比例在甲状腺功能障碍组为3/15(20.0%),无甲状腺功能障碍组为5/133(3.8%),P < .05。
  • 多因素分析中,基线TSH升高、基线TgAb阳性及既往使用雷莫西尤单抗或多靶点酪氨酸激酶抑制剂与甲状腺功能障碍发生显著相关,OR分别为7.098(95% CI 1.154-43.638)、11.927(95% CI 2.526-56.316)、8.476(95% CI 1.592-45.115)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Thyroid dysfunction is frequently caused by treatment with antiprogrammed cell death-1 ligand 1 antibodies (PD-L1-Abs) and anticancer drugs, including ramucirumab (RAM) and multitargeted tyrosine kinase inhibitors (multi-TKIs), which are often used prior to PD-L1-Ab treatment in cancer patients. METHODS: A total of 148 patients treated with PD-L1-Abs were evaluated for antithyroid antibodies at baseline and for thyroid function every 6 weeks for 24 weeks after treatment initiation and then were observed until the visits stopped. RESULTS: Of the 148 patients, 15 (10.1%) developed thyroid dysfunction after PD-L1-Ab treatment (destructive thyroiditis in 8 and hypothyroidism without preceding thyrotoxicosis in 7). The prevalence of an elevated thyroid-stimulating hormone (TSH) level at baseline (3/15 [20.0%] vs 4/133 [3.0%], P < .05), positive antithyroglobulin antibodies (TgAbs) at baseline (4/15 [26.7%] vs 5/133 [3.8%], P < .05) and prior treatment with RAM or multi-TKIs (3/15 [20.0%] vs 5/133 [3.8%], P < .05) were significantly higher in patients with vs without thyroid dysfunction. In a multivariate analysis, elevated TSH level at baseline, TgAb positivity at baseline, and prior treatment with RAM or multi-TKIs were significantly associated with the development of thyroid dysfunction, with ORs of 7.098 (95% CI 1.154-43.638), 11.927 (95% CI 2.526-56.316), and 8.476 (95% CI 1.592-45.115), respectively. CONCLUSION: The results of this real-world study suggest that the risk of thyroid dysfunction induced by PD-L1-Abs can be predicted by the TSH level at baseline, TgAb positivity at baseline, and prior treatment with RAM or multi-TKIs.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Kobayashi T, Iwama S, Yamagami A, et al. Elevated TSH Level, TgAb, and Prior Use of Ramucirumab or TKIs as Risk Factors for Thyroid Dysfunction in PD-L1 Blockade. J Clin Endocrinol Metab. 2022. PMID: 35918067. doi:10.1210/clinem/dgac467

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。